0001936258 2026-07-16 2026-07-16 0001936258 us-gaap:WarrantMember 2026-07-16 2026-07-16 0001936258 us-gaap:CommonStockMember 2026-07-16 2026-07-16 0001936258 true 00-0000000 8-K/A 2026-07-16 NewAmsterdam Pharma Company N.V. P7 001-41562 Goomieer 2-35 Naarden NL 1411 DC 31 (0) 35 206 2971 false false false false Ordinary shares, nominal value €0.12 per share NAMS NASDAQ Warrants to purchase ordinary shares NAMSW NASDAQ false This Amendment No. 1 to Current Report on Form 8-K/A (this “Amendment”) amends the Current Report on Form 8-K filed by NewAmsterdam Pharma Company N.V. (the “Company”) with the Securities and Exchange Commission on July 22, 2026 (the “Original Form 8-K”). In the Original Form 8-K, the Company disclosed its expectation that the Company would enter into a separation agreement and an advisor agreement with Douglas Kling in connection with his resignation as the Company’s Chief Operating Officer to be appointed as the chief executive officer of another clinical-stage biotech company. This Amendment amends the Original Form 8-K solely to provide the terms of such separation and advisor agreements.